LL-37
A natural germ-fighting peptide people try for chronic infections, but the human proof is thin and it can flare some skin diseases.
- What it is
- A germ-fighting peptide your own body already makes
- Is it FDA-approved?
- No, sold for research only
- How strong is the proof?
- Thin: only a few small wound studies, none for shots
- How you take it
- Trials used it on the skin; many inject it
- Typical result
- Helped heal stubborn leg wounds in two small trials
- Biggest catch
- It can make rosacea, psoriasis, and lupus worse
Any word with a dotted underline is a science word — tap it for a plain-English meaning.
In plain words.
LL-37 is a natural your own body makes. Your white blood cells and skin use it to fight germs. It is the only human cathelicidin, which is a family of germ-fighting peptides.
It does two jobs. It can punch holes in germs directly. It also sends signals that steer your immune system. It has 37 building blocks, which is fairly large for a .
It is not . It is sold for research only.
What people use it for.
People use it for chronic infections. The crowd buying it is often dealing with chronic Lyme, mold illness (CIRS), or hard-to-clear infections that form a slimy layer called a biofilm.
These are contested diagnoses. Contested does not mean fake. But it does mean there is often no clear test to tell you if it is working or when to stop. Keep that in mind.
Does it actually work?
What exists is two small wound studies and a mountain of lab work that has never been tested in a living person the way people actually use it.
The only real human trials were small. Two studies, about 30 patients each, used LL-37 placed on top of stubborn venous leg ulcers (open sores on the leg). Those showed it helped the wounds heal.
Here is the gap. That proof is for putting it on a wound on your skin. The Lyme and biofilm crowd usually injects it under the skin instead. That route has almost no human data. There are about 800 lab and animal studies, but those do not replace human trials.
what you’ve probably heard.
The claims floating around online, and how true they actually are.
“Inject it and it busts the biofilms behind chronic Lyme.”
unprovenIn a lab dish it does disrupt biofilm. But the way the Lyme crowd uses it, injected under the skin, has almost no human data. The only real human trials were on leg wounds.
“You can stack it with antibiotics for a stronger hit.”
half trueLL-37 is itself a germ-fighter, so pairing it with an antibiotic can raise the toxicity as much as the effect. Do not run the two together without a doctor steering.
“Your body already makes it, so it's totally safe.”
noYour body makes it, but high local levels show up in some skin diseases. So it can flare rosacea, psoriasis, and lupus, and it can trip an immune alarm against your own DNA.
“It heals stubborn wounds.”
mostly trueThat is the one thing with human proof. Two small trials of about 30 patients each, placing it on stubborn leg ulcers, helped them heal. That is dabbing it on a wound, not the injection people actually buy.
How you take it.
The trials that worked used LL-37 placed directly on a skin wound (topical). That readout took about 84 days, or 12 weeks.
Most people in the chronic-infection crowd inject it under the skin instead. That route is basically uncharted in humans, and the right dose is poorly known.
If you run it for infection symptoms, give it a fixed window, say 8 to 12 weeks, and decide up front what "better" would even look like, since there is no lab number to chase here. There is no proven ladder where longer or higher pulls out a win.
What to watch out for.
The serious stuff
LL-37 is part of your immune system, not just a germ-killer. High local levels are actually seen in some skin diseases. So it can make them flare. - Skip it if you have rosacea, psoriasis, or any lupus-type diagnosis. - Do not run it alongside antibiotics without your doctor steering. LL-37 is itself a germ-fighter, so it can boost both the effect and the toxicity of your antibiotic. - Do not run it alongside immune-suppressing drugs. They work against each other.
There is also deeper science worth reading: LL-37 can bind your own DNA and trigger an immune alarm (interferon-alpha). That is the part we would want anyone to read first.
Talk to a real doctor. We are not your doctor.
Where people get it.
Here are the lanes, safest to riskiest.
- Brand. None. No LL-37 exists.
- . Some pharmacies make it with a prescription, about $140–$300 a month. The trial proof is for the skin, so injecting it is off-label.
- Research-only (). The main source, about $45–$120 a month. LL-37 is long and hard to make cleanly, so weak, sub-90% purity is common.
- . Overseas raw, around $6 a month spread out. Paid by crypto, no lab report. The hard synthesis means fakes and wrong-identity vials are common at the cheapest tier.
Always ask for a , a lab report on what is really in the vial.
Our honest take.
The honest read: the only proof that holds up is for dabbing it on a leg wound. The way people actually buy it, injected for chronic infection, has almost no human data behind it. Inject it and you are the test subject.
What sets this one apart from a harmless flyer is the downside. LL-37 is part of your immune system, so it can flare rosacea, psoriasis, and lupus, and it can trip an immune alarm against your own DNA. That is a steep price for an unproven payoff.
So if you go near it, go in clear-eyed: a clean autoimmune history in you and your family, a real doctor watching, and the autoimmune science actually read before you buy, not after.
The studies behind this.
We read the research so you don't have to. Here's where the facts on this page come from.
- 01Segreto F, et al. Cathelicidin LL-37 Expression in Human Breast Implant Capsules. Plastic and reconstructive surgery. 2024;153(5):1066-1073. PMID: 37220260.
- 02Leite ML, et al. The LL-37 domain: A clue to cathelicidin immunomodulatory response?. Peptides. 2023;165:171011. PMID: 37068711.
- 03Memariani H, et al. Antibiofilm properties of cathelicidin LL-37: an in-depth review. World journal of microbiology & biotechnology. 2023;39(4):99. PMID: 36781570.
- 04Wnorowska U, et al. Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications. Journal of nanobiotechnology. 2020;18(1):3. PMID: 31898542.
- 05Memariani M, et al. Antifungal properties of cathelicidin LL-37: current knowledge and future research directions. World journal of microbiology & biotechnology. 2023;40(1):34. PMID: 38057654.
- 06Xi L, et al. Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy. Peptides. 2024;175:171183. PMID: 38423213.
- 07Kilari G, et al. Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes. 2025;1867(3):184410. PMID: 39837472.
- 08Ahmed EM, et al. Human Cathelicidin, LL-37 a potential antiviral therapeutic for Rift Valley Fever Virus in Egypt. Cellular and molecular biology (Noisy-le-Grand, France). 2024;70(8):1-9. PMID: 39262269.
- 09Fabisiak A, et al. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacological reports : PR. 2016;68(4):802-8. PMID: 27117377.
- 10Miao S, et al. Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease. Pharmacological research. 2024;210:107529. PMID: 39615616.
- 11Nagaoka I, et al. Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model. International journal of molecular sciences. 2020;21(17). PMID: 32825174.
- 12Su Y, et al. Engineered Exosomes Containing Cathelicidin/LL-37 Exhibit Multiple Biological Functions. Advanced healthcare materials. 2022;11(20):e2200849. PMID: 35930707.
- 13Chen X, et al. Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2018;47(3):1060-1073. PMID: 29843147.
- 14Suzuki K, et al. Human cathelicidin peptide LL-37 induces endothelial-to-mesenchymal transition. Bioscience, biotechnology, and biochemistry. 2025;89(10):1464-1473. PMID: 40690262.
- 15Suzuki K, et al. Human Cathelicidin Peptide LL-37 Induces Cell Death in Autophagy-Dysfunctional Endothelial Cells. Journal of immunology (Baltimore, Md. : 1950). 2022;208(9):2163-2172. PMID: 35387840.
- 16Piktel E, et al. The Role of Cathelicidin LL-37 in Cancer Development. Archivum immunologiae et therapiae experimentalis. 2016;64(1):33-46. PMID: 26395996.
- 17Liang J, et al. Cathelicidin LL-37 improves bone metabolic balance in rats with ovariectomy-induced osteoporosis via the Wnt/beta-catenin pathway. Physiological research. 2022;71(3):369-377. PMID: 35616038.
- 18Bucki R, et al. Cathelicidin LL-37: a multitask antimicrobial peptide. Archivum immunologiae et therapiae experimentalis. 2010;58(1):15-25. PMID: 20049649.
- 19Bandurska K, et al. Unique features of human cathelicidin LL-37. BioFactors (Oxford, England). 2015;41(5):289-300. PMID: 26434733.
- 20Aidoukovitch A, et al. Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications. 2024;712-713:149962. PMID: 38642493.
- 21Si F, et al. Cathelicidin (LL-37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4-NF-κB-NLRP3 signaling. Immunity, inflammation and disease. 2023;11(9):e1032. PMID: 37773705.
- 22Ikutama R, et al. Cathelicidin LL-37 Activates Human Keratinocyte Autophagy through the P2X₇, Mechanistic Target of Rapamycin, and MAPK Pathways. The Journal of investigative dermatology. 2023;143(5):751-761.e7. PMID: 36455652.
- 23Sun L, et al. The Roles of Cathelicidin LL-37 in Inflammatory Bowel Disease. Inflammatory bowel diseases. 2016;22(8):1986-91. PMID: 27135484.
- 24Lee JY, et al. Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii. Diagnostic microbiology and infectious disease. 2020;96(4):114965. PMID: 32019695.
- 25Majewska M, et al. Interaction of LL-37 human cathelicidin peptide with a model microbial-like lipid membrane. Bioelectrochemistry (Amsterdam, Netherlands). 2021;141:107842. PMID: 34049238.
- 26Zhang H, et al. Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model. Cell adhesion & migration. 2023;17(1):20-34. PMID: 36656313.
- 27Voronko OE, et al. Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications. International journal of molecular sciences. 2025;26(16). PMID: 40869425.
- 28Croitoru DO, et al. Cathelicidin LL-37 Ignites Primed NLRP3 Inflammasomes in Rosacea. The Journal of investigative dermatology. 2021;141(12):2780-2782. PMID: 34565561.
- 29He Y, et al. Cathelicidin LL-37 in periodontitis: current research advances and future prospects - A review. International immunopharmacology. 2025;150:114277. PMID: 39954662.
- 30Wang G, et al. Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37. Advances in experimental medicine and biology. 2019;1117:215-240. PMID: 30980360.
- 31Aloul KM, et al. Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis. Frontiers in immunology. 2022;13:880961. PMID: 35634307.
- 32Fang Y, et al. Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences. 2026;69(2):492-505. PMID: 40971038.
- 33Zielke C, et al. Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids. Biophysical journal. 2024;123(11):1316-1328. PMID: 37919905.
- 34Golec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. Annals of agricultural and environmental medicine : AAEM. 2007;14(1):1-4. PMID: 17655171.
- 35Shih CC, et al. Antimicrobial peptide cathelicidin LL-37 preserves intestinal barrier and organ function in rats with heat stroke. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023;161:114565. PMID: 36958193.
- 36Cheah CW, et al. Salivary and serum cathelicidin LL-37 levels in subjects with rheumatoid arthritis and chronic periodontitis. International journal of rheumatic diseases. 2020;23(10):1344-1352. PMID: 32743970.
- 37Ahmed A, et al. Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections. Antiviral research. 2019;164:61-69. PMID: 30738837.
- 38Cirone KM, et al. Synthetic cathelicidin LL-37 reduces Mycobacterium avium subsp. paratuberculosis internalization and pro-inflammatory cytokines in macrophages. Cell and tissue research. 2020;379(1):207-217. PMID: 31478135.
- 39Chieosilapatham P, et al. Tissue-specific Regulation of Innate Immune Responses by Human Cathelicidin LL-37. Current pharmaceutical design. 2018;24(10):1079-1091. PMID: 29589544.
- 40Fang X, et al. Human cathelicidin LL-37 exerts amelioration effects against EHEC O157:H7 infection regarding inflammation, enteric dysbacteriosis, and impairment of gut barrier function. Peptides. 2023;159:170903. PMID: 36370932.
- 41Xhindoli D, et al. The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator. Biochimica et biophysica acta. 2016;1858(3):546-66. PMID: 26556394.
- 42Kulkarni NN, et al. Sequence determinants in the cathelicidin LL-37 that promote inflammation via presentation of RNA to scavenger receptors. The Journal of biological chemistry. 2021;297(1):100828. PMID: 34048712.
- 43Nijnik A, et al. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Current opinion in hematology. 2009;16(1):41-7. PMID: 19068548.
- 44Kozłowska E, et al. Serum levels of peptide cathelicidin LL-37 in elderly patients with depression. Psychiatry research. 2017;255:156-160. PMID: 28550757.
- 45Abdelaal NH, et al. Cathelicidin (LL-37) level in the scalp hair of patients with tinea capitis. Medical mycology. 2017;55(7):733-736. PMID: 27915299.
- 46Elgarhy LH, et al. Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research. 2025;317(1):316. PMID: 39873762.
- 47Yanagisawa T, et al. Human cathelicidin antimicrobial peptide LL-37 promotes lymphangiogenesis in lymphatic endothelial cells through the ERK and Akt signaling pathways. Molecular biology reports. 2020;47(9):6841-6854. PMID: 32886325.
- 48Porter RJ, et al. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8(+) T cell infiltrate. The journal of pathology. Clinical research. 2021;7(5):495-506. PMID: 33988317.
- 49Porto WF, et al. In silico assessment of missense point mutations on human cathelicidin LL-37. Journal of molecular graphics & modelling. 2023;118:108368. PMID: 36335830.
- 50Wlodarczyk J, et al. Increased cathelicidin LL-37 colonic expression is associated with tumor progression in colorectal cancer. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2025;76(6):707-715. PMID: 41569060.
- 51Chernov AN, et al. Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. Molecules (Basel, Switzerland). 2022;27(15). PMID: 35956937.
- 52Mańkowska A, et al. Significance of the LL-37 Peptide Delivered from Human Cathelicidin in the Pathogenesis, Treatment, and Diagnosis of Sepsis. Archivum immunologiae et therapiae experimentalis. 2025;73(1). PMID: 40960088.
- 53Gedik AH, et al. Cathelicidin (LL-37) and human β2-defensin levels of children with post-infectious bronchiolitis obliterans. The clinical respiratory journal. 2017;11(2):243-247. PMID: 26073571.
- 54Majewski K, et al. Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases. Journal of biological regulators and homeostatic agents. 2017;31(3):731-736. PMID: 28956425.
- 55Zhang H, et al. Bactericidal synergism between phage endolysin Ply2660 and cathelicidin LL-37 against vancomycin-resistant Enterococcus faecalis biofilms. NPJ biofilms and microbiomes. 2023;9(1):16. PMID: 37024490.
- 56Méndez-Samperio P. The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections. Peptides. 2010;31(9):1791-8. PMID: 20600427.
- 57Tjabringa GS, et al. The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung. Pulmonary pharmacology & therapeutics. 2005;18(5):321-7. PMID: 15939310.
- 58Agier J, et al. Cathelicidin LL-37 Affects Surface and Intracellular Toll-Like Receptor Expression in Tissue Mast Cells. Journal of immunology research. 2018;2018:7357162. PMID: 29670923.
- 59Salvado MD, et al. Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Arteriosclerosis, thrombosis, and vascular biology. 2013;33(8):1965-72. PMID: 23766266.
- 60Johansson L, et al. Cathelicidin LL-37 in severe Streptococcus pyogenes soft tissue infections in humans. Infection and immunity. 2008;76(8):3399-404. PMID: 18490458.
Learn about these too.
We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.
Want the rest of the peptide world, in plain English?
New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.